Tag archive for ‘Johnson & Johnson’
Telaprevir Has Significant Therapeutic and Blockbuster Sales Potential for Hepatitis C (JNJ, $64.95)
The landscape for treating hepatitis C virus is on the verge of dramatic change due to the development of new classes of drugs offering significant improvements in efficacy, convenience and tolerability over the current standard of care which is pegylated alpha interferon combined with ribavirin. The first of the new drugs are protease inhibitors: Vertex/JNJ’s […]
Abiraterone is Significant Advance in Prostate Cancer Treatment (JNJ, $64.11)
I recently recommended purchase of Johnson & Johnson (JNJ) in a report on April 24, 2010 called Johnson & Johnson Looks Promising on New Product Potential. The major factor driving the recommendation is my view that JNJ will be launching two drugs with blockbuster potential in mid-2011. One of these is abiraterone, the subject of […]
Hopes for Rivaroxaban Are Dashed (JNJ, $65.00)
Investment Opinion The FDA problems encountered with rivaroxaban are a significant, but not crushing negative for the investment thesis of Johnson & Johnson (JNJ). I would still be buyer of the stock. This is a very large company not overly dependent on any one current or future product and still has an excellent new drug […]